

Eighth EULAR Scientifically Endorsed Course on Systemic Lupus Erythematosus
Pisa, Italy
May 21-26, 2017

Preliminary Programme

Sunday, May 21, 2017

Arrival and registration of the participants

Chairpersons: S. Bombardieri, M. Galeazzi

| | | |
|----------------|-----------------------|--|
| 15.00 – 15.30: | M. Galeazzi | Welcome address <i>President of the Italian Society of Rheumatology</i> |
| 15.30 – 16.00 | M. Mosca | Course presentation |
| 16.00 – 16.30 | S. Bombardieri | The clinical spectrum of systemic autoimmunity: from UCTD to complex syndromes |
| 16.30 – 17.00 | K. Lerstrom | A difficult journey: living with lupus |
| 17.00 – 17.30 | A. Rossi | Diet and SLE: the importance of the Mediterranean diet |

Monday, May 22, 2017

Morning

Pathogenesis of SLE

Chairpersons: Y. Shoenfeld, M. Cutolo

| | | |
|---------------|----------------------|--------------------------------------|
| 09.00 – 09.30 | Y. Shoenfeld | Environment and autoimmunity |
| 09.30 – 10.00 | R. Voll | B cells in SLE |
| 10.00 – 10.30 | P. Migliorini | Pathogenetic antibodies in SLE |
| 10.30 – 11.00 | | <i>Coffee break</i> |
| 11.00 – 11.30 | M. Cutolo | Hormone D and SLE |
| 11.30 – 12.00 | A. Doria | Pathogenesis and therapeutic targets |

Afternoon

Skin involvement

Chairperson: M. Mosca

| | | |
|---------------|-------------------|--|
| 15.00 – 15.30 | M. Caproni | Overview of cutaneous manifestations in SLE |
| 15.30 – 16.00 | A. Kuhn | Treatment of cutaneous manifestations in SLE |
| 16.00 – 16.15 | | <i>Coffee break</i> |
| 16.15 – 17.15 | | Case Study Workshop <i>Chairperson:</i> A. Kuhn <i>Discussant:</i> tbd Management of cutaneous manifestations in clinical practice |

Tuesday, May 23, 2017

Morning

Highlights of SLE treatment

Chairpersons: M. Schneider, N. Costedoat

| | | |
|---------------|---|--|
| 09.00 – 09.30 | G. Ruiz-Irastorza | Corticosteroid: principles of therapy and monitoring |
| 09.30 – 10.00 | N. Costedoat | Antimalarials and adherence to therapy in SLE |
| 10.00 – 10.30 | G. Bertias | “Traditional drugs” in SLE. Focus on immunosuppressive drugs |
| 10.30 – 11.00 | <i>Coffee break</i> | |
| 11.00 – 11.30 | M. Schneider | New therapies in SLE |
| 11.30 – 12.00 | A. Voskuyl | Treat-to-target in SLE: yes or no? |
| 12.00 – 13.00 | Case Study Workshop <i>Chairperson: G. Ruiz-Irastorza</i> <i>Discussant: C. Tani</i> Real life experience on the use of new biological drugs in clinical practice | |

Afternoon

Kidney involvement

Chairpersons: F. Houssiau, G. Moroni

| | | |
|---------------|---|--|
| 15.00 – 15.30 | J.M. Pego-Reigosa | Epidemiology and outcomes in lupus nephritis. Literature data and the experience of the RELESSER study group |
| 15.30 – 16.00 | G. Moroni | Clinical features and biomarkers |
| 16.00 – 16.30 | F. Houssiau | Therapeutic algorithms in lupus nephritis |
| 16.30 – 16.45 | <i>Coffee break</i> | |
| 16.45 – 18.00 | Discussion of difficult clinical cases on kidney involvement | |

Wednesday, May 24, 2017

Morning

Pregnancy and SLE

Chairpersons: A. Tincani, M. Ostensen

| | | |
|---------------|---|--|
| 09.00 – 09.30 | A. Tincani | Contraception, prevention of infertility and hormonal therapy in SLE |
| 09.30 – 10.00 | M. Ostensen | Drug therapy and toxicity in pregnancy and lactation |
| 10.00 – 10.30 | R. Fischer-Betz | Outcome of pregnancy in patients with SLE |
| 10.30 – 11.00 | <i>Coffee break</i> | |
| 11.00 – 11.30 | L. Andreoli | Hughes syndrome, pregnancy and puerperium |
| 11.30 – 12.00 | F. Strigini | Pregnancy and rheumatic diseases: the obstetrician point of view |
| 12.00 – 13.00 | Case Study Workshop <i>Chairman: R. Fischer-Betz</i> <i>Discussant: R. Vagelli</i> Management of contraception and pregnancy in clinical practice | |

Afternoon: FREE

Thursday, May 25, 2017

Morning

Assessment of SLE in clinical trials and routine clinical practice

Chairpersons: M. Aringer, M. Jolly

| | | |
|---------------|-----------------|---|
| 09.00 – 09.30 | M. Mosca | Early SLE and undifferentiated connective tissue diseases |
|---------------|-----------------|---|

09.30 – 10.00 **M. Aringer** SLE classification criteria: something new?
10.00 – 10.30 **M. Jolly** Fatigue and patient reported outcomes and communication gaps in SLE

10.30 – 11.00 *Coffee break*

11.00 – 11.30 **P.L. Meroni** Comorbidities and SLE
11.30 – 12.00 **C. Tani** SLE, rheumatoid arthritis and overlap syndromes

12.00 – 13.00 **Discussion of difficult clinical cases on NPSLE**

Afternoon

CNS involvement

Chairpersons: D. Boumpas, T. Huizinga

15.00 – 15.30 **T. Huizinga** Pathogenesis of CNS involvement in SLE
15.30 – 16.00 **M. Govoni** The picture of neuropsychiatric lupus
16.00 – 16.30 **D.T. Boumpas** Treatment of NPSLE

16.30 – 16.45 *Coffee break*

16.45 – 18.00 **Discussion of difficult clinical cases on NPSLE**

Friday, May 26, 2017

Morning

SLE and other conditions

Chairpersons: R. Cervera, A.G. Tzioufas

09.00 – 09.30 **I. Bruce** Activity and damage assessment in trials and in clinical practice
09.30 – 10.00 **R. Cervera** Registries and SLE (vorrebbe parlare venerdì)
10.00 – 10.30 **A. Tzioufas** SLE and Sjogren's syndrome
10.30 – 11.00 **C. Baldini** Pulmonary involvement and pulmonary hypertension in SLE and related conditions

11.00 – 11.15 Course conclusions

11.15 – 12.00 Completion of CME tests and departure of the participants